RePORT International Resources

Several training packages.

This three-part webinar series by the Stop TB Partnership and FIND provides an in-depth overview of targeted next-generation sequencing (tNGS) technology for detecting drug-resistant tuberculosis. The series covers fundamental principles of tNGS, its advantages over traditional diagnostic methods, and practical guidance on implementing tNGS in high-burden and resource-limited settings. Featuring expert insights and case studies, the webinars highlight early program experiences and discuss how tNGS supports WHO-endorsed strategies to improve rapid and comprehensive detection of TB drug resistance worldwide.

This website features TAG’s latest updates in the fight to end HIV/AIDS, Hepatitis C, and Tuberculosis. It includes the Pipeline Report on innovations in diagnosing, preventing, treating, and curing HIV, HCV, and TB; information on TB research funding; recorded webinars; advocacy letters and comments submitted or endorsed by TAG; and official press releases and statements.

This report includes an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB) by Treatment Action Group.

Please refer to the link for the TAG's latest edition of TB Treatment Pipeline Report. The report provides the latest information on 22 new or repurposed drugs in clinical development for TB and summarizes ongoing, planned, and recently completed trials. Included in this year's report are: Results from the phase 3 endTB-Q trial and two phase 2b/c trials of quabodepistat-containing regimens completed or discontinued in 2024; First-of-their-kind trials focused on asymptomatic TB and bedaquiline-resistant TB; The first long-acting formulation of a TB drug to enter clinical development; and The first phase 3 trial of a new drug from a new class since bedaquiline and delamanid.

The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB. The Activist Guide reviews the evidence-base behind these regimens, important considerations for key populations affected by TB, the access landscape, and more. The publication is intended to equip advocates with information they need to formulate arguments and push for universal implementation of the best available treatments.

TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.

To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:

The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs. Despite this progress, 2.7 million individuals with TB still remain undiagnosed and undetected. On July 17th, 2025, TAG hosted a community webinar on tests for TB and drug resistance. The webinar breaks down the latest WHO guidelines and explores the most effective tools for diagnosing TB and drug resistance. The webinar also launched TAG’s updated resource, An Activist’s Guide to Diagnostic Tools for Tuberculosis, and provides a deep dive into two sections of the Guide: (1) the array of WHO-recommended diagnostic tools and how they should be optimally used in country programs; and (2) key access considerations and actions activists can take to ensure that all people at risk of TB receive quality TB diagnostic testing.

From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first-of-its-kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines. QS-21 and MPL are part of licensed vaccines against malaria, shingles, and respiratory syncytial virus, and in a promising candidate vaccine for tuberculosis (TB) called M72/AS01E.

From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance ‚ QS-21 and MPL provides a first-of-its-kind analysis of the global supply chains of two key adjuvants used in several of the world‚ most important vaccines. QS-21 and MPL are part of licensed vaccines against malaria, shingles, and respiratory syncytial virus, and in a promising candidate vaccine for tuberculosis (TB) called M72/AS01E.

With the Global Fund Grant Cycle 8 (GC8) now open, this factsheet comes at a critical time for countries preparing funding requests, cost roadmaps, and advocacy strategies to secure NPOC rollout. GC8 is a critical opportunity to shape how new TB diagnostics are financed and deployed over the next grant cycle. TAG‚ new factsheet gives advocates the tools needed to succeed: clear budget language, use case illustrations, advocacy questions for country dialogues, and a step-by-step timeline spanning the full funding cycle.

What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, written together with community partners and supported by Wellcome, explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their success once they become available.

This is a summary of the presentations from the TB Alliance Global TB Stakeholders meeting on March 4, 2026.

The Tuberculosis Data, Impact Assessment and Communications Hub (TB DIAH) supports decision-makers by generating, analyzing, and utilizing quality data to inform and scale up effective TB services. This website provides resources on TB M&E and surveillance processes.

A report has been published based on findings of the study conducted in Ukraine: “Studying the Aspects of Gender, Equity, and Inclusion in the Workplace Among Healthcare Professionals Involved in TB Response" https://tbcoalition.eu/resource/files/2025/09/report-on-gender-assessment-among-healthcare-workers-in-ukraine_eng.pdf The aim of the study was to assess the level of implementation of gender equality principles among healthcare workers providing TB diagnostic and treatment services, and to examine the barriers preventing women and men from exercising their right to gender equality. The study employed a triangulation method, which ensured the validity and reliability of the results. As part of this approach, the following methods were used: Desk review, In-depth interviews, Focus group discussions.

National Association of Tuberculosis Patients of the Republic of Moldova “SMIT” published a report with the results of the study ‚ Multidimensional Analysis of Tuberculosis-Related Stigma in the Republic of Moldova. The study was conducted at the request of the National TB Response Program, with the support of the Center for Health Policies and Studies and the TB Europe Coalition, and funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Stop TB Partnership. The assessment was conducted in 2025 and provides a structured analysis of the barriers to accessing human rights-based, gender-sensitive, and population-specific TB care.

This website features TBEC's resources ranging from different publications to various capacity building tools such CSOs map or TBEC webinar recordings, please see below a short overview of different international and regional institutions and organisations, fighting against TB in the WHO Europe region and globally. All of the websites contain valuable sources of information and capacity building tools that you will find helpful in your advocacy in the WHO Europe region and globally.

TBEC’s mission is to strengthen the role and contribution of civil society organisations (CSOs) and affected communities within a sustainable and effective response to TB across in the region by: Providing a coordinating body that unites TB advocates across the region, in order to disseminate information, promote collaboration and learning, and share best practice; Building the advocacy capacity and coordinate the strategies of TB advocates and CSOs across the region; Leveraging the political and financial commitment

This webinar is aimed at strengthening the knowledge and advocacy capacity of civil society representatives and TB-affected communities in Eastern Europe and Central Asia (EECA). Participants will learn about the mechanisms of drug pricing and access, as well as effective advocacy strategies for WHO-recommended short, fully oral regimens for drug-resistant TB (DR-TB). The event will help link global discussions on access to medicines with community-level action, enhancing participants‚ ability to advocate for equitable, sustainable, and people-centered TB treatment scale-up. The event is part of the "The ABC for TB Activist" webinar series and is organized by the TB Europe Coalition in partnership with the Centre for Global Health Policy & Politics (GHPP) and the Treatment Action Group (TAG) within the Combat DR-TB interregional project, funded by Unitaid.